andrew seidman, md: different mechanisms of action in eribulin
Published 8 years ago • 440 plays • Length 1:34Download video MP4
Download video MP3
Similar videos
-
1:34
andrew seidman, md: main indications for dose reduction with eribulin
-
0:58
andrew seidman, md: candidacy for eribulin therapy
-
0:49
andrew seidman, md: efficacy data supporting the use of eribulin mesylate
-
1:10
dr. andrew d. seidman on targeted treatments in breast cancer
-
1:20
dr. andrew d. seidman on the lack of a biomarker in certain breast cancers
-
0:44
andrew seidman, md: third-line options to prolong life
-
4:12
eribulin in recurrent metastatic er breast cancer
-
0:54
dr. seidman on ixabepilone in patients with aggressive breast cancer
-
0:48
andrew seidman, md: treatment goals for patients with tnbc
-
1:58
dr. alvarez on updated findings with eribulin in patients with her2 breast cancer
-
6:09
dual moa for eribulin in breast cancer
-
1:58
dr. twelves on a pooled analysis of eribulin in breast cancer
-
1:48
dr. andrew seidman discusses the management of patients with brain metastases
-
1:23
dr. kaufman discusses the use of eribulin in metastatic breast cancer
-
1:06
dr. vahdat on capecitabine and eribulin in advanced breast cancer
-
6:51
treatment with eribulin mesylate in metastatic breast cancer
-
2:19
dr. twelves discusses eribulin for the treatment of breast cancer
-
1:20
dr. o’shaughnessy on eribulin as first-line therapy for metastatic her2-negative breast cancer
-
1:13:00
expanding the benefits of parp inhibitors to more patients with breast cancer and earlier settings